Autres langues STADA Arzneimittel

Actions

SAZ

DE0007251803

Produits pharmaceutiques

Temps Différé Xetra			Varia. 5j.	Varia. 1 janv.
- ^EUR	-.--%		-1,95%	-8,87%

10/11/23	Alvotech et Stada obtiennent le soutien du comité de l'UE pour le biosimilaire de Stelara	MT
25/07/23	Xbrane Biopharma et Stada envisagent des options pour le ranibizumab	FW

Autres langues

23/03/25	Beursgangen: de drie IPO's om in 2025 in de gaten te houden
09/01/25	Pharmakonzern Stada vor milliardenschwerem Börsengang
11/09/24	Beteiligungsfirma GTCR erwägt laut Medienberichten milliardenschweren Stada-Kauf
26/07/24	Calliditas partner STADA receives European Commission decision for full approval of Kinpeygo® for the treatment of IgA Nephropathy
30/05/24	Calliditas partner STADA receives positive CHMP opinion recommending full approval for Kinpeygo[®] for the treatment of IgA nephropathy
29/05/24	Bio-Thera and STADA Reach Exclusive Agreement for BAT2506, a Proposed Golimumab Biosimilar, in the EU and UK
10/05/24	Xbrane and STADA partner with Valorum Biologics to commercialize ranibizumab biosimilar candidate in the US
14/03/24	Arzneikonzern Stada wächst - Finanzinvestoren prüfen Ausstieg
04/03/24	Xbrane has received additional subscription undertakings corresponding to approximately SEK 18.1 million in the Company's rights issue
10/11/23	Alvotech, Stada Get EU Panel Backing for Stelara Biosimilar
03/10/23	Calliditas announces filing with UK MHRA for Kinpeygo in IgA nephropathy
28/09/23	STADA and Calliditas announce the filing for full marketing authorization of Kinpeygo® in the EU
15/08/23	Calliditas Therapeutics announces full results from the NefIgArd Phase 3 trial published in The Lancet
25/07/23	STADA and Xbrane weigh options for ranibizumab biosimilar candidate
21/06/23	Xbrane announce U.S. FDA filing acceptance for a Lucentis® (ranibizumab) biosimilar candidate
26/05/23	STADA AND XBRANE LAUNCH XIMLUCI AS RANIBIZUMAB BIOSIMILAR IN GERMANY
26/05/23	STADA and Xbrane launch Ximluci® as ranibizumab biosimilar in Germany
26/04/23	STADA AND XBRANE SUPPLY XIMLUCI IN ENGLAND UNDER NHS CONTRACT
25/04/23	STADA and Xbrane supply Ximluci® (ranibizumab) in England under NHS contract
03/04/23	STADA and Xbrane launch ranibizumab to support patient access in Europe
23/02/23	AFR: STADA Arzneimittel AG: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß § 114, 115, 117 WpHG
23/02/23	AFR: STADA Arzneimittel AG: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß § 114, 115, 117 WpHG
08/02/23	European Biosimilar Regulatory Updates
02/02/23	Calliditas Receives Conditional Marketing Authorization from UK MHRA for Kinpeygo in IgA nephropathy
17/01/23	STADA and Xbrane obtain British approval for Ximluci® (ranibizumab) biosimilar referencing Lucentis®